A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

NCT07164170 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

NCT03866980 ·Status: TERMINATED ·Phase: PHASE3

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NCT05636267 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

NCT06452433 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

NCT06890182 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

NCT06436144 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

NCT06634667 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126 ·Status: COMPLETED ·Phase: PHASE1

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

NCT02215356 ·Status: UNKNOWN ·Phase: PHASE2

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 ·Status: UNKNOWN ·Phase: PHASE3

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

NCT06786312 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NCT05991206 ·Status: RECRUITING

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

NCT03636685 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

NCT02031601 ·Status: UNKNOWN ·Phase: PHASE4

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

NCT06196814 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

NCT02103257 ·Status: UNKNOWN ·Phase: PHASE4

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

NCT06334757 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

NCT07279935 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4